BioGend Therapeutics , Ltd. Profit Margin

The latest profit margin for 6733.TWO is -29.75% as of June 2026. That compares with -65.18% in the prior-year period — up 54.4% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside BioGend Therapeutics , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 6733.TWO's profit margin moved from -65.18% to -29.75% — a 54.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioGend Therapeutics , Ltd.'s valuation or profitability profile.

Against Healthcare companies, 6733.TWO currently prints -29.75% for profit margin, while the sector average sits near 21.34%. That is roughly 239.4% below the sector mean. Large gaps often invite a closer look at BioGend Therapeutics , Ltd.'s growth, margins, and balance sheet.

Profit Margin shows how effectively BioGend Therapeutics , Ltd. converts resources into returns. At -29.75%, 6733.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -65.18% in the prior-year period — up 54.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 6733.TWO's profit margin (-29.75%), review year-over-year change from -65.18%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.